Next Article in Journal
Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma—An Evaluation of Predictors
Previous Article in Journal
Lymphoma-Associated Biomarkers Are Increased in Current Smokers in Twin Pairs Discordant for Smoking
Previous Article in Special Issue
Deep Learning Segmentation of Triple-Negative Breast Cancer (TNBC) Patient Derived Tumor Xenograft (PDX) and Sensitivity of Radiomic Pipeline to Tumor Probability Boundary
Article

Development and Validation of an Efficient MRI Radiomics Signature for Improving the Predictive Performance of 1p/19q Co-Deletion in Lower-Grade Gliomas

1
International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
2
Department of Thoracic Surgery, Khanh Hoa General Hospital, Nha Trang City 65000, Vietnam
3
Department of Orthopedic and Trauma, Cho Ray Hospital, Ho Chi Minh City 70000, Vietnam
4
Professional Master Program in Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University, Taipei 106, Taiwan
5
Research Center for Artificial Intelligence in Medicine, Taipei Medical University, Taipei 106, Taiwan
6
Translational Imaging Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan
*
Author to whom correspondence should be addressed.
Academic Editors: David Wong and Sibaji Sarkar
Cancers 2021, 13(21), 5398; https://doi.org/10.3390/cancers13215398
Received: 23 August 2021 / Revised: 19 October 2021 / Accepted: 26 October 2021 / Published: 27 October 2021
(This article belongs to the Collection Radiomics and Cancers)
Low-grade gliomas (LGG) with the 1p/19q co-deletion mutation have been proven to have a better survival prognosis and response to treatment than individuals without the mutation. Identifying this mutation has a vital role in managing LGG patients; however, the current diagnostic gold standard, including the brain-tissue biopsy or the surgical resection of the tumor, remains highly invasive and time-consuming. We proposed a model based on the eXtreme Gradient Boosting (XGBoost) classifier to detect 1p/19q co-deletion mutation using non-invasive medical images. The performance of our model achieved 87% and 82.8% accuracy on the training and external test set, respectively. Significantly, the prediction was based on only seven optimal wavelet radiomics features extracted from brain Magnetic Resonance (MR) images. We believe that this model can address clinicians in the rapid diagnosis of clinical 1p/19q co-deletion mutation, thereby improving the treatment prognosis of LGG patients.
The prognosis and treatment plans for patients diagnosed with low-grade gliomas (LGGs) may significantly be improved if there is evidence of chromosome 1p/19q co-deletion mutation. Many studies proved that the codeletion status of 1p/19q enhances the sensitivity of the tumor to different types of therapeutics. However, the current clinical gold standard of detecting this chromosomal mutation remains invasive and poses implicit risks to patients. Radiomics features derived from medical images have been used as a new approach for non-invasive diagnosis and clinical decisions. This study proposed an eXtreme Gradient Boosting (XGBoost)-based model to predict the 1p/19q codeletion status in a binary classification task. We trained our model on the public database extracted from The Cancer Imaging Archive (TCIA), including 159 LGG patients with 1p/19q co-deletion mutation status. The XGBoost was the baseline algorithm, and we combined the SHapley Additive exPlanations (SHAP) analysis to select the seven most optimal radiomics features to build the final predictive model. Our final model achieved an accuracy of 87% and 82.8% on the training set and external test set, respectively. With seven wavelet radiomics features, our XGBoost-based model can identify the 1p/19q codeletion status in LGG-diagnosed patients for better management and address the drawbacks of invasive gold-standard tests in clinical practice. View Full-Text
Keywords: low-grade gliomas; radiogenomics; machine learning; chromosome 1p/19q codeletion; molecular subtype; wavelet transform; magnetic resonance imaging; precision medicine; computer aided diagnosis; decision making low-grade gliomas; radiogenomics; machine learning; chromosome 1p/19q codeletion; molecular subtype; wavelet transform; magnetic resonance imaging; precision medicine; computer aided diagnosis; decision making
Show Figures

Figure 1

MDPI and ACS Style

Kha, Q.-H.; Le, V.-H.; Hung, T.N.K.; Le, N.Q.K. Development and Validation of an Efficient MRI Radiomics Signature for Improving the Predictive Performance of 1p/19q Co-Deletion in Lower-Grade Gliomas. Cancers 2021, 13, 5398. https://doi.org/10.3390/cancers13215398

AMA Style

Kha Q-H, Le V-H, Hung TNK, Le NQK. Development and Validation of an Efficient MRI Radiomics Signature for Improving the Predictive Performance of 1p/19q Co-Deletion in Lower-Grade Gliomas. Cancers. 2021; 13(21):5398. https://doi.org/10.3390/cancers13215398

Chicago/Turabian Style

Kha, Quang-Hien, Viet-Huan Le, Truong N.K. Hung, and Nguyen Q.K. Le 2021. "Development and Validation of an Efficient MRI Radiomics Signature for Improving the Predictive Performance of 1p/19q Co-Deletion in Lower-Grade Gliomas" Cancers 13, no. 21: 5398. https://doi.org/10.3390/cancers13215398

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop